

May 1, 2026

Pharmacy Exception Request – Brand Name Toujeo (Insulin Glargine)

Patient: Jules Arden

DOB: 11/9/1971

Member ID: KPX658320914

Group ID: 238714

Diagnosis: E11.9

Dear Medical Review Department,

I am writing to request a formulary exception and prior authorization approval for my patient, Jules Arden, to receive brand-name Toujeo (insulin glargine U-300) based on medical necessity. This request is being made due to clinical concerns regarding the use of formulary-preferred basal insulin alternatives. I am an Authorized Representative for the patient.

Jules Arden requires long-acting basal insulin as part of a comprehensive diabetes management regimen. Based on the patient's clinical profile, Toujeo is the most appropriate basal insulin due to its pharmacokinetic properties, including a more stable and prolonged duration of action with a flatter profile compared to standard U-100 insulin glargine formulations. These characteristics are particularly important for minimizing glycemic variability and reducing the risk of hypoglycemia.

Formulary-preferred basal insulin alternatives, including standard insulin glargine U-100 products and biosimilars, are not appropriate for this patient due to the increased risk of peak-related hypoglycemia and inconsistent glucose control. In patients requiring precise basal coverage, differences in concentration and absorption can lead to clinically significant variability.

Requiring this patient to trial formulary alternatives would pose an unnecessary medical risk, including increased likelihood of hypoglycemic events and destabilization of glycemic control. This request meets the criteria for a formulary exception based on:

- The preferred alternatives are not medically appropriate for this patient
- Use of alternatives is likely to result in adverse clinical outcomes, including hypoglycemia and glucose variability

- The requested medication provides clinically superior stability and safety for this patient's needs

Given these considerations, I respectfully request approval for brand-name Toujeo without substitution. Please contact my office if additional documentation is required.

Sincerely,

Dr. Avery Solis, MD
Endocrinologist
Griffin Medical Center
4827 Silver Mesa Drive
Las Vegas, NV 89117
Phone: (702) 555-8431
Fax: (702) 555-8436
NPI: 1493015826

Prescription**Prescriber:**

Dr. Avery Solis, MD
4827 Silver Mesa Drive
Las Vegas, NV 89117
Phone: (702) 555-8431
NPI: 1493015826

Patient: Jules Arden

DOB: 11/09/1971

Medication:

Toujeo (insulin glargine U-300) 300 units/mL injection

Sig (Directions):

Inject subcutaneously 20 units once daily at the same time each day, titrate dose based on fasting blood glucose as directed.

Dispense:

1 box (3 prefilled pens, 1.5 mL each)

Refills:

3

Substitution:

Dispense as written (DAW 1) – do not substitute

Indication:

Diabetes mellitus requiring basal insulin

Date: 5/1/2026

Prescriber Signature: _____

